Brimonidine Induced Anterior Uveitis

Beltz, Jacqueline; Zamir, Ehud

doi:10.3109/09273948.2015.1037845

Cited by 36 publications

(28 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, multiple linear regression analysis indicated a negative correlation between anterior flare reduction and combination therapy of K-115 and α2-agonists, which suggests that α2-agonists with or without K-115 possibly increase anterior inflammation in uveitis with OHT. Previous reports have proposed that adrenergic agonists decrease the volume of conjunctival cells and widen the space between cells, allowing greater access of pro-inflammatory agents and continued topical administration of α2-agonists in eyes with allergic reactions may predispose to the development of uveitis [ 24 ]. Histological findings of conjunctivitis and anterior uveitis induced by α2-agonists have also been reported [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension

et al. 2017

View full text Add to dashboard Cite

Ocular hypertension (OHT) caused by inflammation or corticosteroid treatment is a common complication of uveitis. Ripasudil hydrochloride hydrate (K-115) is reportedly efficacious for lowering intraocular pressure (IOP). We retrospectively compared the IOP-lowering effect of K-115 for inflammatory and corticosteroid-induced OHT associated with uveitis. Thirty-six consecutive eyes of 27 patients with uveitis-associated OHT (20 and 16 eyes with inflammation- and corticosteroid-induced OHT, respectively) were treated with K-115 with or without other anti-glaucoma agents. In the inflammation-induced OHT, mean IOP and aqueous flare significantly decreased (P < 0.001 and P = 0.035, respectively), changing from 26.4 ± 7.5 mmHg and 28.1 ± 15.0 photon counts per millisecond (pc/ms) at the initial assessment to 17.9 ± 5.4 mmHg and 17.1 ± 10.7 pc/ms at the last visit, respectively. In the corticosteroid-induced OHT, mean IOP significantly decreased (P = 0.0005), changing from 26.7 ± 7.8 mmHg and 18.7 ± 11.2 pc/ms to 18.6 ± 8.8 mmHg and 22.6 ± 15.3 pc/ms, respectively; conversely, aqueous flare remained unchanged. In the inflammation-induced OHT, K-115 was more efficacious in the eyes with higher IOP. Neither remarkable adverse effects nor exacerbation of uveitis were observed in the eyes of either group during the observation period. K-115 decreased IOP in both inflammation- and corticosteroid-induced OHT associated with uveitis and played a synergistic role in reducing ocular inflammation in uveitis treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Three previous studies have investigated the role of topical pharmaceutical agents on leukocyte migration [26,31,32]. However, only one examined multiple antiglaucomatous drugs, including beta blockers, cholinergic agonists and nonselective adrenergic agonists [26].…”

Section: Discussionmentioning

confidence: 99%

The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations

Alonso

Solari

Damasceno

et al. 2020

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

Background: The study aimed to evaluate and compare the leukocyte chemotactic activities of various brimonidine tartrate (BT) eye drop formulations. Methods: A 96-well dot-blot platet using a Boyden-style well was used to study the chemotactic effects of BT ophthalmic preparations. A modification was made to create blind wells where the tested agents were placed. Leukocytes were isolated from the peripheral blood of healthy volunteers. As positive controls, we used diluted drugs, benzalkonium chloride solution (BAK), zymosan-activated serum, and formyl-methionine-leucinephenylalanine peptides. The negative control in our study was a phosphate-buffered saline solution. For each experimental condition, we measured leukocyte migration through a Millipore membrane. The differences in the mean migration distance between groups were compared using the analysis of variance (ANOVA). Results: The measured migration distances (in μm ± SD) were 62.14 ± 3.71 for BT 0.2% with BAK (Alcon Laboratories Inc.); 63.61 ± 3.81 for BT 0.2% with BAK (Allergan Inc); 40.36 ± 3.17 for BT 0.15% without BAK; and 41.02 ± 2.17 for BAK alone. The negative controls showed no chemotactic activity, while the positive controls showed the highest neutrophil migration of all experimental conditions. The differences between BT 0.15% without BAK and the other commercial formulations were statistically significant. Conclusion: Commercial ophthalmic preparations of BT 0.2% with BAK 0.005% had higher chemotactic properties than the alternative of a lower concentration of BT and without the preservative BAK. Therefore, the latter should be considered for patients with glaucoma or ocular hypertension in order to minimize iatrogenic ocular inflammation.

show abstract

“…При терапии бримонидином описано развитие гранулематозного конъюнктивита и кровоизлияний в конъюнктиву [44,50]. Фолликулярный конъюнктивит считается частой реакцией на простагландины, ингибиторы карбоангидразы, α2-адреномиметики.…”

Section: переносимость антиглаукомной терапии и побочные эффекты актиunclassified

The effect of the main active substances of antihypertensive eye drops on condition of the eyes of glaucoma patients

Онуфрийчук

Газизова

Куроедов

et al. 2020

Tihookeanskij medicinskij žurnal

View full text Add to dashboard Cite

Today, glaucoma is considered to be the most common cause of irreversible blindness. The treatment of this disease is aimed at reducing intraocular tension in order to slow down the deterioration of visual functions and to maintain accept‑ able quality of life. Most ophthalmologists prefer local medicamentous therapy. Despite a significant expansion of the range of antihypertensive medicines, a significant increase in the hypotensive effect is not always achieved in each certain case, at the same time, at long-term (sometimes lifetime) treatment local and systemic adverse reactions arise and intensify. The findings of recent clinical trials presented in this overview demonstrate an adverse effect of active compounds, preservatives and ad‑ ditives of ophthalmic medicines not only on the eye surface but also on the structure of anterior and posterior eye segments. Taking into account possible side effects of each component of medicines used in glaucoma therapy, ophthalmologists will be able to reasonably approach the choice of optimal treatment regimens with the lowest risk for patients.

show abstract

Brimonidine Induced Anterior Uveitis

Abstract: Ophthalmologists should be aware of this easily reversible uveitis syndrome that is induced by a common glaucoma medication. Familiarity with this entity is essential in making the correct diagnosis and avoiding unnecessary investigations and interventions.

Cited by 36 publications

References 22 publications

Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension

Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension

The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations

The effect of the main active substances of antihypertensive eye drops on condition of the eyes of glaucoma patients

Contact Info

Product

Resources

About